LBRX (LB Pharmaceuticals) Total Debt per Share: $0.12 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LBRX LB Pharmaceuticals Inc LBRX
12 GF Score
Price $32.09
! 1 Warning Sign
View Full Analysis

What is LB Pharmaceuticals Total Debt per Share?

LB Pharmaceuticals LBRX +0.21% 12 Total Debt per Share is $0.12 as of Mar. 2026. GuruFocus rates LBRX with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

$0.12 (As of Mar. 2026)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. LB Pharmaceuticals's Total Debt Per Share for the quarter that ended in Mar. 2026 was $0.12.

LB Pharmaceuticals Total Debt per Share Historical Data

* Premium members only.

The historical data trend for LB Pharmaceuticals's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LB Pharmaceuticals Total Debt per Share Chart

LB Pharmaceuticals Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Debt per Share
1.08 0.00 0.17 0.14

LB Pharmaceuticals Quarterly Data
Dec22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.17 0.15 0.14 0.12
LBRX
12GF Score
LB Pharmaceuticals Inc LBRX
Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LB Pharmaceuticals Total Debt per Share Calculation

LB Pharmaceuticals's Total Debt Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(2.84+0.73)/25.30
=0.14

LB Pharmaceuticals's Total Debt Per Share for the quarter that ended in Mar. 2026 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(2.74+0.73)/28.68
=0.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of $0.12 mean?
LB Pharmaceuticals (LBRX) has a Total Debt per Share of $0.12 as of Mar. 2026. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on LB Pharmaceuticals and its competitors.
Is LB Pharmaceuticals' Total Debt per Share too high?
LB Pharmaceuticals' current Total Debt per Share is $0.12. Overall, LB Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does LB Pharmaceuticals' Total Debt per Share compare to MRVI and SLDB?
LB Pharmaceuticals' Total Debt per Share of $0.12 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Biotechnology company?
A good Total Debt per Share depends on the Biotechnology industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on LB Pharmaceuticals and its competitors. LB Pharmaceuticals's current Total Debt per Share is $0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LB Pharmaceuticals stock overvalued right now?
LB Pharmaceuticals (LBRX) has a current Total Debt per Share of $0.12. The current Total Debt per Share is $0.12. LB Pharmaceuticals' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For LB Pharmaceuticals (LBRX), the current Total Debt per Share is $0.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LB Pharmaceuticals Business Description

Address One Pennsylvania Plaza, Suite 1025, New York, NY, USA, 10119
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
12GF Score

Get the complete analysis for LBRX

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$32.09
Price